Anavex Life Sciences’ (AVXL) “Buy” Rating Reaffirmed at D. Boral Capital

Anavex Life Sciences (NASDAQ:AVXL)‘s stock had its “buy” rating reissued by investment analysts at D. Boral Capital in a report issued on Monday,Benzinga reports. They presently have a $24.00 target price on the biotechnology company’s stock. D. Boral Capital’s target price suggests a potential upside of 434.52% from the company’s current price.

A number of other brokerages have also recently issued reports on AVXL. Weiss Ratings reissued a “sell (d-)” rating on shares of Anavex Life Sciences in a report on Monday, December 29th. HC Wainwright reiterated a “buy” rating and set a $20.00 price target on shares of Anavex Life Sciences in a research report on Tuesday, February 10th. Finally, Wall Street Zen raised Anavex Life Sciences from a “sell” rating to a “hold” rating in a report on Saturday, February 14th. Two analysts have rated the stock with a Buy rating, one has given a Hold rating and one has given a Sell rating to the company’s stock. According to MarketBeat, Anavex Life Sciences presently has a consensus rating of “Hold” and a consensus target price of $22.00.

Anavex Life Sciences Stock Performance

Shares of NASDAQ AVXL traded up $0.43 during trading on Monday, reaching $4.49. The stock had a trading volume of 525,056 shares, compared to its average volume of 1,294,182. The stock has a market cap of $416.09 million, a PE ratio of -9.75 and a beta of 1.08. Anavex Life Sciences has a one year low of $2.86 and a one year high of $13.99. The firm’s 50 day moving average price is $4.52 and its two-hundred day moving average price is $5.80.

Anavex Life Sciences (NASDAQ:AVXL) last released its quarterly earnings data on Monday, February 9th. The biotechnology company reported ($0.06) EPS for the quarter, topping analysts’ consensus estimates of ($0.10) by $0.04. On average, research analysts expect that Anavex Life Sciences will post -0.69 earnings per share for the current year.

Institutional Inflows and Outflows

Several institutional investors and hedge funds have recently bought and sold shares of AVXL. State Street Corp raised its holdings in shares of Anavex Life Sciences by 33.4% during the fourth quarter. State Street Corp now owns 4,383,406 shares of the biotechnology company’s stock valued at $15,605,000 after buying an additional 1,096,288 shares during the last quarter. Geode Capital Management LLC grew its holdings in Anavex Life Sciences by 2.8% in the 2nd quarter. Geode Capital Management LLC now owns 2,019,795 shares of the biotechnology company’s stock worth $18,624,000 after buying an additional 54,985 shares in the last quarter. Two Sigma Investments LP increased its position in Anavex Life Sciences by 6.5% in the 3rd quarter. Two Sigma Investments LP now owns 1,036,954 shares of the biotechnology company’s stock valued at $9,229,000 after acquiring an additional 63,685 shares during the period. Summit Financial LLC increased its position in Anavex Life Sciences by 103.3% in the 4th quarter. Summit Financial LLC now owns 903,392 shares of the biotechnology company’s stock valued at $3,216,000 after acquiring an additional 459,121 shares during the period. Finally, Goldman Sachs Group Inc. raised its stake in Anavex Life Sciences by 187.7% during the 4th quarter. Goldman Sachs Group Inc. now owns 872,968 shares of the biotechnology company’s stock valued at $3,108,000 after acquiring an additional 569,579 shares in the last quarter. Institutional investors own 31.55% of the company’s stock.

Anavex Life Sciences Company Profile

Anavex Life Sciences Corp is a clinical‐stage biopharmaceutical company focused on the development of novel therapeutics for central nervous system (CNS) disorders. The company applies a proprietary drug discovery platform that targets sigma‐1 and muscarinic receptors to modulate cellular stress pathways and support neuronal function. Headquartered in New York City, Anavex is dedicated to advancing treatments for neurodegenerative and neurodevelopmental diseases with high unmet medical need.

The company’s lead product candidate, blarcamesine (ANAVEX2‐73), is a small‐molecule activator of the sigma‐1 receptor currently being evaluated in clinical trials for Alzheimer’s disease and Parkinson’s disease dementia.